Optiray (Ioversol)

Optiray (ioversol) is used as a radiographic contrast agent to improve visualization of vascular and organ structures during imaging procedures.

• Angiography: enhances visualization of blood vessels to aid diagnosis and interventional procedures.
• Computed tomography (CT) imaging: provides contrast enhancement for better delineation of anatomical structures.
• Urography: improves detection of urinary tract abnormalities by highlighting kidneys, ureters, and bladder.
• Venography: facilitates clear imaging of the venous system for assessment of thrombosis or obstruction.

• Ioversol contains a high density of iodine atoms that absorb X‑ray photons. When administered intravenously or intra‑arterially, the iodine atoms increase the attenuation of X‑rays passing through blood, tissues and organs, creating a temporary difference in radiodensity between vascular structures and surrounding tissues. This contrast enhancement allows radiologists to distinguish anatomical details and pathological changes on fluoroscopic, CT or digital subtraction imaging studies.

Adverse reactions to Optiray are generally related to its iodine content and the physiological response to the injected solution.

Common Side Effects

• Warmth or flushing sensation at the injection site.
• Metallic taste in the mouth.
• Nausea or mild vomiting.
• Headache or dizziness.

Serious or Rare Side Effects

• Severe allergic reactions, including anaphylaxis.
• Acute kidney injury in susceptible patients.
• Persistent hypotension or cardiovascular collapse.
• Seizures or neurological disturbances.

Before administering Optiray, clinicians should evaluate patient-specific factors and follow handling guidelines to minimize risk.

• Assess renal function: check serum creatinine and eGFR to determine suitability.
• Review allergy history: identify prior reactions to iodinated contrast agents.
• Use the lowest effective volume: limit iodine load especially in at‑risk patients.
• Monitor vital signs: observe blood pressure and heart rate during and after injection.
• Avoid in patients with known iodine hypersensitivity unless benefits outweigh risks.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Optiray may interact with certain medications, altering safety or efficacy.

Major Interactions (Avoid)

• Metformin: concurrent use can increase risk of lactic acidosis in renal impairment; discontinue metformin before and after contrast administration.
• Thyroid hormone preparations: excess iodine may exacerbate hyperthyroidism; monitor thyroid function.
• Nephrotoxic drugs (e.g., aminoglycosides, amphotericin B): combined use raises risk of renal injury.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask tachycardia associated with contrast reactions.
• ACE inhibitors or ARBs: can potentiate contrast‑induced nephropathy; consider temporary suspension.
• Diuretics: may affect fluid balance and renal clearance of iodine.
• NSAIDs: increase risk of renal dysfunction when combined with contrast.